Physician profile
Matthew Bessen
NPI 1780672402
$4,806.55
in general payments reported to CMS, 2019-2025
23 companies · $351 in 2025
The $351 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $403 · 2021: $1,578 · 2022: $652 · 2023: $531 · 2024: $797 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,505.11 | 2019-2025 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $382.31 | 2019-2024 | |
| Amgen INC. | $375.01 | 2019-2024 | Repatha |
| Pfizer INC. | $283.37 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $271.59 | 2019-2022 | |
| Boston Scientific Corporation | $235.70 | 2022-2025 | Watchman Flx |
| Irhythm Technologies, INC. | $224.86 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $222.46 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $200.19 | 2019-2025 | Camzyos, Eliquis |
| Medicure Pharma INC. | $136.52 | 2020 | |
| Medtronic, INC. | $133.34 | 2024 | Aurora Ev-Icd Mri Surescan, Symplicity G3 |
| Novo Nordisk INC | $127.25 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.83 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $103.43 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $78.29 | 2019-2023 | Brilinta, Wainua |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $72.80 | 2019-2023 | |
| Cvrx, INC. | $64.35 | 2022 | |
| Alnylam Pharmaceuticals INC. | $63.24 | 2019-2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $56.52 | 2021-2022 | |
| Esperion Therapeutics, INC. | $55.45 | 2021 | |
| Scpharmaceuticals INC. | $44.22 | 2025 | |
| Kestra Medical Technology Services, INC. | $34.10 | 2024 | Assure Wcd |
| Otsuka America Pharmaceutical, INC. | $16.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bessen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.